Eprenetapopt combination improves outcomes in TP53-mutated AML, myelodysplastic syndrome

Eprenetapopt plus azacitidine maintenance therapy significantly improved outcomes for patients with TP53-mutated acute myeloid leukemia and TP53-mutated myelodysplastic syndrome, according to study results.
Asmita Mishra, MD, assistant member of the department of blood and marrow transplant at H. Lee Moffitt Cancer Center and Research Institute and assistant professor of oncology at University of South Florida, presented the phase 2 trial results at Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR.
“Relapse remains the number one cause of transplant

Eprenetapopt plus azacitidine maintenance therapy significantly improved outcomes for patients with TP53-mutated acute myeloid leukemia and TP53-mutated myelodysplastic syndrome, according to study results.
Asmita Mishra, MD, assistant member of the department of blood and marrow transplant at H. Lee Moffitt Cancer Center and Research Institute and assistant professor of oncology at University of South Florida, presented the phase 2 trial results at Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR.
“Relapse remains the number one cause of transplant